Blog
RSS FeedPosted by Michael Wonder on 20 May 2020
Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan
18 May 2020 - In Japan, a new cost-effectiveness evaluation system for medicine and medical device pricing was employed in April ...
Posted by Michael Wonder on 20 May 2020
Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work?
20 May 2020 - On April 29, the National Institutes of Health announced that in a placebo-controlled trial of patients with ...
Posted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...
Posted by Michael Wonder on 10 May 2020
COVID-19 raises questions about the value of personalised medicine
8 May 2020 - A group of medical dissenters argues that tailoring treatment to the genetic profiles of individuals, a longstanding ...
Posted by Michael Wonder on 07 May 2020
How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?
7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...
Posted by Michael Wonder on 04 May 2020
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
1 May 2020 - The reimbursement of the immune checkpoint inhibitors is challenging. ...
Posted by Michael Wonder on 01 May 2020
Swiss study sees no link between cancer drug prices and patient benefits
1 May 2020 - New research from the University of Zurich renews calls for more transparency in the way drug ...
Posted by Michael Wonder on 30 Apr 2020
Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?
30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...
Posted by Michael Wonder on 10 Mar 2020
Inappropriate use of progression-free survival in cancer drug approvals
10 March 2020 - New drugs should be judged on overall survival or quality of life, preferably both. ...
Posted by Michael Wonder on 10 Mar 2020
New brand-name HIV prevention pill not worth the added cost
10 March 2020 - A cheaper HIV prevention pill is going on sale soon in the U.S., but the price ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 20 Jan 2020
Why cancelling your private health insurance could have unintended consequences
20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...
Posted by Michael Wonder on 17 Jan 2020
Pricing of pharmaceuticals is becoming a major challenge for health systems
13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...
Posted by Michael Wonder on 17 Jan 2020
Defining the concept of fair pricing for medicines
13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...